logo-loader
viewReNeuron Group PLC

Full interview: 'All systems go' for ReNeuron's retinitis pigmentosa programme as it looks to follow-up studies

ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they've seen a 'rapid and profound' result in the first three patients of the second phase of clinical studies of its human retinal progenitor cells (hRPC).

''What we're seeing is hugely encouraging and I think the principal investigator will make that clear when he presents the data next weekend''.

Quick facts: ReNeuron Group PLC

Price: 151 GBX

LSE:RENE
Market: LSE
Market Cap: £48.07 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating...

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott following the release of new positive data relating to its CTX cell therapy candidate which has been published in the peer-reviewed scientific journal Stem Cells. He says the new data shows for the first...

2 weeks ago

2 min read